Literature DB >> 31934585

Evolving Treatment Paradigms for Pancreatic Cancer.

Rami Abbassi1, Roland M Schmid1.   

Abstract

BACKGROUND: Pancreatic adenocarcinoma is an extremely aggressive tumor which is supposed to become the second deadliest malignancy in 2030. For a long time the possibilities to treat this complex disease were very limited.
SUMMARY: In the last years the development of new chemotherapeutic regimens has led to a better outcome in the ad-juvant, neoadjuvant, and palliative setting. Furthermore, progress in sequencing technologies has enabled a detailed investigation of the genetic alterations, mutational burden, expression pattern, and stroma composition in pancreatic cancer and led to the identification of subtypes of this disease. MESSAGES: This analysis will increase our understanding of tumor heterogeneity and hopefully translate into new potential targets, biomarkers, and the development of individual therapeutic approaches in the future.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Chemotherapy; Individualized treatment; Pancreatic cancer; Pancreatic cancer heterogeneity; Pancreatic cancer subtypes

Year:  2019        PMID: 31934585      PMCID: PMC6944930          DOI: 10.1159/000503797

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  35 in total

1.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

2.  A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth.

Authors:  Giulia Biffi; David A Tuveson
Journal:  Cancer Discov       Date:  2019-05       Impact factor: 39.397

3.  Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.

Authors:  Martin Wartenberg; Silvia Cibin; Inti Zlobec; Erik Vassella; Serenella Eppenberger-Castori; Luigi Terracciano; Micha David Eichmann; Mathias Worni; Beat Gloor; Aurel Perren; Eva Karamitopoulou
Journal:  Clin Cancer Res       Date:  2018-04-16       Impact factor: 12.531

4.  Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.

Authors:  Quisette P Janssen; Stefan Buettner; Mustafa Suker; Berend R Beumer; Pietro Addeo; Philippe Bachellier; Nathan Bahary; Tanios Bekaii-Saab; Maria A Bali; Marc G Besselink; Brian A Boone; Ian Chau; Stephen Clarke; Mary Dillhoff; Bassel F El-Rayes; Jessica M Frakes; Derek Grose; Peter J Hosein; Nigel B Jamieson; Ammar A Javed; Khurum Khan; Kyu-Pyo Kim; Song Cheol Kim; Sunhee S Kim; Andrew H Ko; Jill Lacy; Georgios A Margonis; Martin D McCarter; Colin J McKay; Eric A Mellon; Sing Yu Moorcraft; Ken-Ichi Okada; Alessandro Paniccia; Parag J Parikh; Niek A Peters; Hans Rabl; Jaswinder Samra; Christoph Tinchon; Geertjan van Tienhoven; Eran van Veldhuisen; Andrea Wang-Gillam; Matthew J Weiss; Johanna W Wilmink; Hiroki Yamaue; Marjolein Y V Homs; Casper H J van Eijck; Matthew H G Katz; Bas Groot Koerkamp
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

5.  Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.

Authors:  Ken-Ichi Okada; Seiko Hirono; Manabu Kawai; Motoki Miyazawa; Atsushi Shimizu; Yuji Kitahata; Masaki Ueno; Shinya Hayami; Hiroki Yamaue
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.480

6.  Whole genomes redefine the mutational landscape of pancreatic cancer.

Authors:  Nicola Waddell; Marina Pajic; Ann-Marie Patch; David K Chang; Karin S Kassahn; Peter Bailey; Amber L Johns; David Miller; Katia Nones; Kelly Quek; Michael C J Quinn; Alan J Robertson; Muhammad Z H Fadlullah; Tim J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Craig Nourse; Ehsan Nourbakhsh; Shivangi Wani; Peter J Wilson; Emma Markham; Nicole Cloonan; Matthew J Anderson; J Lynn Fink; Oliver Holmes; Stephen H Kazakoff; Conrad Leonard; Felicity Newell; Barsha Poudel; Sarah Song; Darrin Taylor; Nick Waddell; Scott Wood; Qinying Xu; Jianmin Wu; Mark Pinese; Mark J Cowley; Hong C Lee; Marc D Jones; Adnan M Nagrial; Jeremy Humphris; Lorraine A Chantrill; Venessa Chin; Angela M Steinmann; Amanda Mawson; Emily S Humphrey; Emily K Colvin; Angela Chou; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Pettitt; Neil D Merrett; Christopher Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Nigel B Jamieson; Janet S Graham; Simone P Niclou; Rolf Bjerkvig; Robert Grützmann; Daniela Aust; Ralph H Hruban; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Massimo Falconi; Giuseppe Zamboni; Giampaolo Tortora; Margaret A Tempero; Anthony J Gill; James R Eshleman; Christian Pilarsky; Aldo Scarpa; Elizabeth A Musgrove; John V Pearson; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2015-02-26       Impact factor: 49.962

7.  Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Authors:  M Haas; J T Siveke; M Schenk; M M Lerch; K Caca; J Freiberg-Richter; L Fischer von Weikersthal; F Kullmann; A Reinacher-Schick; M Fuchs; S Kanzler; V Kunzmann; T J Ettrich; S Kruger; C B Westphalen; S Held; V Heinemann; S Boeck
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

8.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

9.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

10.  Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

Authors:  Lilian Schwarz; Dewi Vernerey; Jean-Baptiste Bachet; Jean-Jacques Tuech; Fabienne Portales; Pierre Michel; Antonio Sa Cunha
Journal:  BMC Cancer       Date:  2018-07-24       Impact factor: 4.430

View more
  2 in total

Review 1.  Therapeutic Intervention in Cancer by Isoliquiritigenin from Licorice: A Natural Antioxidant and Redox Regulator.

Authors:  Zhu Zhang; Ken Kin-Lam Yung; Joshua Ka-Shun Ko
Journal:  Antioxidants (Basel)       Date:  2022-07-11

Review 2.  Targeting the Stroma in the Management of Pancreatic Cancer.

Authors:  Penelope Edwards; Byung Woog Kang; Ian Chau
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.